Scilone Pharma Inlicenses China marketing rights to ProFlow® - A treatment for Peripheral Arterial disease

SciClone Pharmaceuticals, Inc. will pay to Taiwan Liposome Company (TLC) upto $39.5 million as and when certain clinical, regulatory and sales related milestones are achieved. Under the terms of the agreement, TLC will be responsible for the continued development, including potential clinical trials and regulatory activities, as well as the manufacturing and supply of ProFlow, and SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities. ProFlow has been submitted to the China Food and Drug Administration (CFDA) for approval, and it is expected that some additional clinical testing may be required prior to approval.  Taiwan Liposome company has given the Japan rights for ProFlow to Nihon Generic company.